Korea Reimburses Gilead's Sovaldi, Harvoni To Aid Access
This article was originally published in PharmAsia News
Executive Summary
With China and Japan moving to cut prices of Gilead's blockbuster hepatitis C drugs Sovaldi and Harvoni, South Korea has decided to reimburse the products from May. Although not all HCV genotypes will be covered by national health insurance, the move will sharply ease local patients' cost burden amid an outbreak of infections last year.
You may also be interested in...
Korea Moves To Halt Reuse Of Disposable Devices Amid HCV Outbreak
South Korean measures to root out the reuse of disposable medical devices amid a local outbreak of hepatitis C may have a positive impact on the industry, but the government still has some barriers to cross as industry participants are calling for more comprehensive measures.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.
Window Of Opportunity: Korea Unveils Cutting-Edge Bio Initiative
South Korea is moving forward with plan to set up a Boston-type biotech cluster in Osong as part of a broader initiative unveiled by President Yoon, while the biopharma industry is calling for rapid process, exceptional support.